BuTrans in moderate chronic pain

BuTrans (buprenorphine) patches are now indicated in the management of non-malignant moderate chronic pain when an opioid is necessary for obtaining adequate analgesia.

The lowest strength (5 microgram/hr) patch should be used initially and the dose may be increased after three days; when the maximum effect of a given dose is established. The dose should be titrated according to the patient's analgesic response to the BuTrans patch and the need for supplemental pain relief.

View BuTrans drug record

Further information: Napp

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Elleste Duet, Elleste Solo, Diprosone and Livial.

Potentially addictive medicines 'being prescribed for years'

Potentially addictive medicines 'being prescribed for years'

Hundreds of thousands of people are receiving prescriptions...